Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded Contacts/Locations and Study Status sections to the study record history, updating the list of locations and the current status. A deletion occurred on 2025-09-05.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter revision updated to v3.3.2, replacing v3.2.0.SummaryDifference0.0%

- Check29 days agoChange DetectedRemoved the banner that stated potential delays due to government funding and NIH operating status from the page; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check44 days agoChange DetectedThe record history now shows additional submission versions, expanding the list of past updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference8%

- Check80 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.